Effect of BAS 100 on erlotinib pharmacokinetics
Author Information
Author(s): Smith N F, Baker S D, Gonzalez F J, Harris J W, Figg W D, Sparreboom A
Primary Institution: National Cancer Institute
Hypothesis
The study aims to evaluate the effect of CYP3A4 inhibition by BAS 100 on the pharmacokinetics of erlotinib in mice.
Conclusion
BAS 100 significantly increased the systemic exposure of erlotinib following oral administration in mice.
Supporting Evidence
- BAS 100 resulted in a 2.1-fold increase in erlotinib exposure.
- The study suggests that BAS 100 enhances the oral bioavailability of erlotinib.
- BAS 100 did not change the metabolism of erlotinib into its active metabolite OSI-420.
Takeaway
BAS 100, a substance from grapefruit juice, helps increase the amount of erlotinib that gets into the body, which could help cancer patients get better treatment.
Methodology
The study involved administering BAS 100 and erlotinib to mice and measuring plasma concentrations to assess pharmacokinetics.
Limitations
The study was conducted in mice, and results may not directly translate to humans.
Participant Demographics
Female BALB/c and CYP3A4 transgenic mice, aged 6–14 weeks.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website